Here are the 10-Q quarterly reports from Lifeward Ltd. (LFWD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LFWD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LFWD filings page.
Lifeward Ltd. (LFWD) reported third-quarter revenue of $5.428 million, down from $6.195 million a year earlier, and a net loss of $5.052 million versus $3.170 million. ReWalk revenue fell $1.3 million, mainly from lower U.S. and European sales and near-term effects of its transition to channel partners; higher AlterG revenue partly offset the decline. Nine-month revenue was $15.974 million versus $16.953 million, and net loss was $27.364 million versus $14.566 million. Acquired Oratech in-process research and development generated $4.947 million in nine-month R&D expense.
During the first nine months, operating activities used $16.064 million in cash and financing activities provided $18.502 million; cash and cash equivalents were $4.548 million as of September 30, 2026. Management concluded existing cash resources were insufficient to fund planned operations for at least 12 months from issuance and that substantial doubt exists about Lifeward’s ability to continue as a going concern. Lifeward plans to raise additional capital.
In November 2026, a Belgian authority said it believes Neo and Neo+ Anti-Gravity Treadmills should be classified at least as Class IIa devices. Lifeward is evaluating and implementing corrective actions; it does not currently expect EU marketing to be interrupted during the applicable transition period, while marketing afterward depends on timely completion of the regulatory process.
Lifeward Ltd. reported second-quarter 2026 revenue of $6.6 million, up modestly from $5.7 million a year earlier, with six-month revenue essentially flat at $10.5 million versus $10.8 million in 2025. Gross profit for the first half was $4.1 million, down from $4.6 million.
The company posted a six‑month net loss of $22.3 million, nearly double the prior-year loss of $11.4 million, driven largely by $7.8 million in net financial expense from warrant and derivative liabilities and interest on new convertible notes. Operating cash outflow was $9.7 million. Management states that recurring losses, negative cash flows and limited liquidity raise substantial doubt about Lifeward’s ability to continue as a going concern without additional financing.
During the period, Lifeward closed the Oratech asset acquisition, allocating $4.9 million to in‑process R&D (expensed immediately) and $6.5 million to acquired cash, and completed the Skelable technology acquisition. It also issued $10 million of senior secured convertible notes with attached warrants and, in a July closing, added $5.6 million more in senior secured convertible notes, while reclassifying certain warrant and derivative liabilities to equity.
Lifeward Ltd. reported a sharply wider quarterly loss while closing a major strategic transaction and related financing. For the three months ended March 31, 2026, revenue was $3.9 million, down from $5.0 million, mainly from lower AlterG Anti-Gravity system shipments, and gross margin fell to 34.2% from 42.2%. Net loss increased to $10.8 million, driven largely by a one-time $4.9 million acquired in‑process R&D charge from the Oratech asset acquisition and higher interest expense on new convertible notes. On March 25, 2026, Lifeward acquired Oratech for total consideration of about $12.4 million and issued $10.0 million of secured convertible notes and related warrants to Oramed and Creative Value Capital at a $5.40 per share conversion price. Cash and cash equivalents rose to $11.4 million after the Oratech cash acquired and note financing, but the company disclosed an accumulated deficit of $295.5 million and concluded that “substantial doubt” exists about its ability to continue as a going concern without additional capital.
Lifeward Ltd. reported lower revenues and widening losses in the quarter ended June 30, 2025. Quarterly revenue was $5.7 million versus $6.7 million a year earlier, and six‑month revenue totaled $10.8 million versus $12.0 million. The company recorded a quarterly operating loss of $6.6 million and a six‑month net loss of $11.4 million. Cash and cash equivalents were $5.1 million at June 30, 2025 and total cash, cash equivalents and restricted cash were $5.5 million, with management estimating runway into the fourth quarter of 2025, raising substantial doubt about going concern.
The company recorded a $2.8 million goodwill impairment in Q2 2025 and eliminated an earnout liability. Lifeward completed multiple 2025 equity financings, including a January registered direct offering and a June public offering (4.0 million shares with warrants), and raised proceeds under an ATM program (964,118 shares sold for net proceeds of about $1.0 million). A favorable Administrative Law Judge ruling and CMS actions have established a Medicare pathway for ReWalk (HCPCS code K1007) with a lump‑sum purchase payment of $91,032, a material reimbursement development for the ReWalk product line.